We obtained 53 discovery cohorts for this study, including 40,299 SCZ cases and 65,264 controls (Supplementary Figure 4). 52/53 cohorts (35,079 cases, 46,441 controls) were obtained through collaboration with the Psychiatric Genomics Consortium, and are described in the 2014 PGC Schizophrenia GWAS22. The remaining cohort, referred to as CLOZUK2, constitutes the largest single cohort of individuals with Schizophrenia (5,220 cases and 18,823 controls), collected as part of an effort to investigate treatment-resistant Schizophrenia60.
